Oncology Institute, Inc. (DFPH)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Total operating revenue | 119,802 | 104,406 | 99,901 | |
| Direct costs | - | 87,157 | 85,209 | |
| Selling, general and administrative expense | 26,907 | 25,376 | 26,646 | |
| Depreciation and amortization | 1,805 | 1,784 | 1,573 | |
| Direct costs-Health Care Patient Service | 51,150 | - | - | |
| Direct costs-Dispensary Revenue | 51,086 | - | - | |
| Direct costs-Clinical Research Trials And Other Revenue | 65 | - | - | |
| Total operating expenses | 131,013 | 114,317 | 113,754 | |
| Loss from operations | -11,211 | -9,911 | -13,853 | |
| Other, net | -19 | -752 | -55 | |
| Interest expense, net | 1,870 | 5,570 | 2,225 | |
| Change in fair value of derivative warrant liabilities | 53 | 43 | -20 | |
| Change in fair value of conversion option derivative liabilities | -3,987 | -3,309 | - | |
| Total other non-operating loss (income) | -5,929 | -9,674 | -2,260 | |
| Loss before provision for income taxes | -17,140 | -19,585 | -16,113 | |
| Income tax benefit (expense) | -131 | - | - | |
| Net loss | -17,009 | -19,585 | -16,113 | |
| Basic (in dollars per share) | -0.15 | -0.21 | -0.18 | |
| Basic (in shares) | 93,203,665 | 77,098,825 | 75,524,823 | |
| Diluted (in dollars per share) | -0.15 | -0.21 | -0.18 | |
| Diluted (in shares) | 93,203,665 | 77,098,825 | 75,524,823 | |